Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CORAL GABLES, Fla., June 27, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, today provided an update on its progress with its lead investigational product, FIRDAPSETM.
Help employers find you! Check out all the jobs and post your resume.
CORAL GABLES, Fla., June 27, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, today provided an update on its progress with its lead investigational product, FIRDAPSETM.
Help employers find you! Check out all the jobs and post your resume.
